Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Porta Hermanos is a prominent Argentine industrial company that has successfully transitioned from a traditional distillery into a leader in biotechnology and molecular farming. The company is widely recognized for its proprietary molecular farming platform, which utilizes genetically modified safflower seeds to produce high-value recombinant proteins, most notably chymosin for the food industry. In addition to its biotech innovations, Porta is a major regional producer of pharmaceutical-grade alcohol, vinegar, and consumer spirits. Their operations are characterized by a commitment to sustainability, evidenced by their B-Corp certification and the development of modular, eco-friendly distillery technologies. The company's biotech division, BioPorta, continues to explore the production of complex proteins for both industrial and potential therapeutic applications. This unique integration of agriculture and high-tech manufacturing positions Porta as a key player in the global bioeconomy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Porta Hnos.